[Sarcoïdosis and anti-TNF: a paradoxical class effect? Analysis of the French Pharmacovigilance system database and literature review]

Lucie Javot; Stéphane Tala; Julien Scala-Bertola; Nathalie Massy; Thierry Trenque; Bernadette Baldin; Michel Andréjak; Pierre Gillet; Nadine Petitpain; le réseau français des Centres Régionaux de Pharmacovigilance

doi:10.2515/therapie/2011014

[Sarcoïdosis and anti-TNF: a paradoxical class effect? Analysis of the French Pharmacovigilance system database and literature review]

Therapie. 2011 Mar-Apr;66(2):149-54. doi: 10.2515/therapie/2011014. Epub 2011 Jun 6.

[Article in French]

Authors

Lucie Javot¹, Stéphane Tala, Julien Scala-Bertola, Nathalie Massy, Thierry Trenque, Bernadette Baldin, Michel Andréjak, Pierre Gillet, Nadine Petitpain; le réseau français des Centres Régionaux de Pharmacovigilance

Affiliation

¹ Centre Régional de Pharmacovigilance, Hôpital Central, CHU, Nancy, France.

PMID: 21635863
DOI: 10.2515/therapie/2011014

Abstract

Objectives: To identify and characterize the observations of sarcoidosis occurring during anti-TNF blockade collected in the French Pharmacovigilance system database and reported in the literature.

Results: Seven cases were reported in the French Pharmacovigilance system database and 39 cases (37 original) have been reported internationally. Monoclonal antibodies (infliximab and adalimumab) and fusion protein (etanercept) are equally involved. Sarcoidosis have been confirmed histologically and occurred predominantly in the rheumatoid arthritis (22) and spondylarthropathy (16).

Conclusion: The lack of protopathic bias suggests that these paradoxical sarcoidosis occurring during treatment with anti-TNF are a class-effect, as with psoriasis, uveitis, and IBD reported under similar conditions. Their pathogenesis remains unclear.

Publication types

Case Reports

MeSH terms

Adalimumab
Adult
Aged
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized / adverse effects
Antirheumatic Agents / adverse effects
Arthritis, Psoriatic / complications
Arthritis, Psoriatic / drug therapy
Arthritis, Rheumatoid / complications
Arthritis, Rheumatoid / drug therapy
Etanercept
Female
France / epidemiology
Humans
Immunoglobulin G / adverse effects
Infliximab
Male
Middle Aged
Pharmacovigilance
Psoriasis / complications
Psoriasis / drug therapy
Receptors, Tumor Necrosis Factor
Sarcoidosis / chemically induced*
Sarcoidosis / epidemiology
Spondylarthropathies / complications
Spondylarthropathies / drug therapy
Tumor Necrosis Factor Inhibitors*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor Inhibitors
Infliximab
Adalimumab
Etanercept